Last reviewed · How we verify
Usual doses of tigecycline
Tigecycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing peptide elongation.
Tigecycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing peptide elongation. Used for Complicated skin and soft tissue infections, Complicated intra-abdominal infections, Community-acquired bacterial pneumonia.
At a glance
| Generic name | Usual doses of tigecycline |
|---|---|
| Sponsor | Air Force Specialized Hospital, Cairo, Egypt |
| Drug class | Tetracycline antibiotic |
| Target | Bacterial 30S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Tigecycline is a broad-spectrum tetracycline antibiotic that binds to the bacterial 30S ribosomal subunit and blocks the attachment of aminoacyl-tRNA to the A site of the ribosome. This inhibits peptide chain elongation and results in bacteriostatic activity against a wide range of gram-positive, gram-negative, and anaerobic bacteria. It has enhanced activity compared to earlier tetracyclines due to structural modifications that reduce efflux-mediated resistance.
Approved indications
- Complicated skin and soft tissue infections
- Complicated intra-abdominal infections
- Community-acquired bacterial pneumonia
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Photosensitivity
- Increased intracranial pressure
- Tooth discoloration
Key clinical trials
- Clinical Effectiveness of a Once-daily Regimen of Tigecycline Compared to the Standard Regimen (PHASE4)
- Clinical Study of New Intensive Treatment Regimen for Severe Nontuberculous Mycobacterial Pulmonary Disease (PHASE4)
- Best Available Therapy With or Without Meropenem for Bloodstream Infections by Enterobacterales With High Level of Resistance to Carbapenems (PHASE2, PHASE3)
- Pharmacokinetics and Safety of Tigecycline in the Treatment of Clostridium Difficile Associated Diarrhea (CDAD) (NA)
- A Pharmacovigilance Evaluation And Assessment Of The Prescribing Practice For Tygacil In Usual Health Care Setting
- Open Label Non-comparative Clinical Trial of Tigecycline in Patients With Catheter Infection (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Usual doses of tigecycline CI brief — competitive landscape report
- Usual doses of tigecycline updates RSS · CI watch RSS
- Air Force Specialized Hospital, Cairo, Egypt portfolio CI